Core Insights - Avicanna Inc. has initiated a Phase I randomized, double-blinded, placebo-controlled clinical trial to evaluate the dose-dependent effects of oral THC on anxiety and stress, led by researchers at the University of Calgary [1][4] Study Overview - The trial will enroll 24 healthy adult participants who will receive single oral doses of THC at 6 mg, 9 mg, and 15 mg, along with a placebo, with washout periods between dosing sessions [2] - Primary endpoints focus on validated psychometric assessments of anxiety and subjective response, while secondary endpoints include measures of mood, intoxication, cardiovascular parameters, stress biomarkers, endocannabinoid system markers, and pharmacokinetic profiling [2] Investigational Product - The trial utilizes Avicanna's proprietary THC capsules, AVCN319301b, which employ the Solid Self-Emulsifying Drug Delivery System (SEDDs) technology to enhance absorption and reduce variability of onset [3] - Avicanna's SEDDs technology has shown versatility across various drug delivery formats, including liquid infuser drops and capsules, and is also involved in a pilot Phase II RCT for osteoarthritis [3] Company Background - Avicanna is a commercial-stage international biopharmaceutical company focused on the development and commercialization of cannabinoid-based products for the medical and pharmaceutical markets [7] - The company has developed over thirty proprietary, evidence-based finished products and supports four commercial stage business pillars [7]